[{"address1": "1300 South El Camino Real", "address2": "Suite 400", "city": "San Mateo", "state": "CA", "zip": "94402", "country": "United States", "phone": "(650) 781-5200", "website": "https://www.kronosbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.", "fullTimeEmployees": 61, "auditRisk": 9, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.04, "open": 1.04, "dayLow": 1.0, "dayHigh": 1.08, "regularMarketPreviousClose": 1.04, "regularMarketOpen": 1.04, "regularMarketDayLow": 1.0, "regularMarketDayHigh": 1.08, "beta": 1.774, "forwardPE": -0.72, "volume": 271417, "regularMarketVolume": 271417, "averageVolume": 504661, "averageVolume10days": 1042380, "averageDailyVolume10Day": 1042380, "bid": 1.05, "ask": 1.08, "bidSize": 500, "askSize": 400, "marketCap": 64901956, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 2.29, "priceToSalesTrailing12Months": 8.554363, "fiftyDayAverage": 0.98052, "twoHundredDayAverage": 1.105905, "currency": "USD", "enterpriseValue": -59608040, "floatShares": 44637526, "sharesOutstanding": 60094400, "sharesShort": 714072, "sharesShortPriorMonth": 662733, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0119, "heldPercentInsiders": 0.2517, "heldPercentInstitutions": 0.36262, "shortRatio": 1.3, "shortPercentOfFloat": 0.015700001, "impliedSharesOutstanding": 60094400, "bookValue": 2.279, "priceToBook": 0.47389206, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -116393000, "trailingEps": -1.99, "forwardEps": -1.5, "enterpriseToRevenue": -7.857, "enterpriseToEbitda": 0.563, "52WeekChange": -0.3076923, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KRON", "underlyingSymbol": "KRON", "shortName": "Kronos Bio, Inc.", "longName": "Kronos Bio, Inc.", "firstTradeDateEpochUtc": 1602250200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6f8f728e-bb6c-3b57-873b-3a705e9ece7a", "messageBoardId": "finmb_559411734", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.08, "targetHighPrice": 6.0, "targetLowPrice": 2.25, "targetMeanPrice": 4.13, "targetMedianPrice": 4.13, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 151984000, "totalCashPerShare": 2.529, "ebitda": -105890000, "totalDebt": 27474000, "quickRatio": 7.986, "currentRatio": 8.321, "totalRevenue": 7587000, "debtToEquity": 20.059, "revenuePerShare": 0.13, "returnOnAssets": -0.28583, "returnOnEquity": -0.64204, "freeCashflow": -46757376, "operatingCashflow": -96534000, "revenueGrowth": 1.064, "grossMargins": 1.0, "operatingMargins": -7.62222, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]